Buzz Stocks: Wynn Resorts, Limited, AbbVie Inc, and Seres Therapeutics Inc

Today's stocks to watch in the news include Wynn Resorts, Limited (NASDAQ:WYNN), AbbVie Inc (NYSE:ABBV), and Seres Therapeutics Inc (NASDAQ:MCRB)

Jul 29, 2016 at 10:20 AM
facebook twitter linkedin


U.S. stocks are down after a couple of blue-chip earnings misses, and as traders react to weaker-than-expected preliminary gross domestic product (GDP) data. Among equities in focus today are casino stock Wynn Resorts, Limited (NASDAQ:WYNN), as well as biotechs AbbVie Inc (NYSE:ABBV) and Seres Therapeutics Inc (NASDAQ:MCRB).  

  • WYNN is down 7.6% at $96.75, despite reporting earnings that beat analyst expectations. Instead, traders are reacting to the casino's smaller-than-expected allocation of table permits for a new casino in Macau. This news led to a subsequent slew of bearish analyst notes, including a downgrade to "underperform" by CSLA. Nomura cut its rating on WYNN to "reduce" from "neutral," trimmed its price target to $83 from $92, and said "This paltry allocation is a clear message from Beijing that it is serious about Macau enforcing the table cap." Despite the drop, WYNN remains up over 50% year-to-date, although the shares have been running into resistance at the $104-$105 area. WYNN's Schaeffer's put/call open interest ratio (SOIR) of 0.54 sits at the very bottom of its 52-week range, suggesting short-term option players haven't been more call-skewed in the last 12 months.
  • ABBV is up 1.6% at $65.75, after another earnings beat and upwardly revised full-year forecast, citing strong drug sales, especially for its rheumatoid arthritis drug, Humira. This puts AbbVie Inc up nearly 10% since the beginning of 2016, and the shares are now flirting with year-to-date highs. Analysts remain skeptical of ABBV, however, with seven of 13 rating the shares a "hold" or worse, leaving plenty of room for potential upgrades to propel the shares even higher.
  • MCRB is down 76.2% at $8.53 -- a new all-time low – after its experimental drug, SER-109, failed to reach its main goal in a mid-stage study. Nevertheless, H.C. Wainwright subsequently began coverage on MCRB with a "buy" rating and optimistic price target of $50 -- a 486% premium to the stock's new low. MCRB now sits 75% lower year-to-date, and today finds itself on the short-sale restricted list. There are likely plenty of shorts cheering, though, as short interest represents nearly two-and-a-half weeks of pent-up buying demand, at MCRB's average daily volume. 

Don't miss the market's next move! Sign up now for Schaeffer's Midday Market Check

Winning With Weekly Options

1606854690

  


 
Special Offers from Schaeffer's Trading Partners